Navigation Links
NuvaRing Lawsuit Filed by Alonso Krangle on Behalf of a Louisiana Woman Who Developed Pulmonary Embolism Allegedly Due to NuvaRing Use
Date:7/28/2013

New York, NY (PRWEB) July 28, 2013

Alonso Krangle’s attorneys have recently filed a NuvaRing lawsuit against Organon, Merck and others on behalf of a woman from Louisiana. This case (Case No. 2:13-cv-03678-SDW-MCA) was filed June 13, 2013 in the U.S. District Court of New Jersey and specifically names the defendants to be Organon USA, Inc., N.V. Organon, the Schering Corporation, Merck & Co., Inc., and Merck Sharp & Dohme.

In addition to alleging that use of NuvaRing caused the plaintiff to develop a serious lung condition known as pulmonary embolism, this case alleges that Organon and the other defendants knew but failed to publicly disclose the fact that NuvaRing had a higher risk of blood clot-related complications than oral contraceptives. Furthermore, this NuvaRing lawsuit contends that Organon and the other defendants failed to adequately safety test NuvaRing and negligently marketed NuvaRing as a safe and effective birth control medication without warning consumers about the potential risks of serious NuvaRing side effects.

Alonso Krangle’s experienced NuvaRing lawsuit attorneys are dedicated to standing up for victims’ rights and holding even the largest corporations accountable for their potentially dangerous medications. We offer free NuvaRing lawsuit evaluations to those who have sustained serious injuries, such as blood clots and pulmonary embolisms, that could be linked to the use of NuvaRing. To discuss a potential NuvaRing lawsuit claim with one of the compassionate NuvaRing lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website, FightForVictims.com.

According to court documents in this NuvaRing lawsuit, the plaintiff began using NuvaRing in December 2006. After developing chest pain, coughing and shortness of breath, in July 2012, she sought medical attention and underwent a CT scan, at which time she was informed that she had developed multiple pulmonary emboli. Pulmonary emboli are blood clots lodged in the lungs that can severely impair breathing and result in life-threatening complications. Following this diagnosis, the plaintiff was hospitalized for two days, was advised to stop using NuvaRing and was placed under anticoagulation therapy, including Lovenox and Coumadin. While the plaintiff had to continue her anticoagulation therapy after being released from the hospital, she has also had to undergo regular follow-up care to monitor her health.

Risk of Serious Complications Associated with NuvaRing Use

The link between NuvaRing use and the development of serious blood clot disorders like pulmonary embolism has been reported by many medical researchers within recent years. In fact, in 2012, a study published in the New England Journal of Medicine reported that vaginal rings like NuvaRing could nearly triple women’s risk of developing blood clots, when compared to the risk associated with older birth control pills.
( nejm.org/doi/full/10.1056/NEJMoa1111840 )

Another study published in May 2012 in the British Medical Journal found that women’s risk of developing blood clots increased at least 6.5 times when using vaginal rings like NuvaRing, as opposed to birth control pills.
( bmj.com/content/344/bmj.e2990#alternate )

Seeming to support the alleged link between NuvaRing use and serious blood clots is information from the FDA’s Adverse Events Reporting System (AERS), which has received more than 5,350 reports of serious adverse events related to NuvaRing use since the drug was first introduced in 1997 (though FDA approval was not granted until 2001). Among the most commonly reported adverse effects patients reported after NuvaRing use were more than 1,170 incidents of pulmonary embolism and more than 1,150 incidents of thrombosis and deep vein thrombosis. According to the FDA AERS, upwards of 30 percent of women who reported NuvaRing complications required hospitalization, and approximately 3 percent of NuvaRing complications resulted in death.
( adverseevents.com/drugdetail.php?AEDrugID=4584&BrandName=NUVARING )

About Alonso Krangle LLP And Filing A NuvaRing Lawsuit

Andres Alonso and David Krangle, attorneys with almost 40 years of collective legal experience, have dedicated their law practice on handling significant personal injury cases, defective drug and medical device litigation, construction site accidents, nursing home abuse, medical negligence, qui tam/whistleblower actions and consumer fraud cases. Alonso Krangle LLP is offering FREE NuvaRing lawsuit evaluations to those who have sustained serious injuries, such as blood clots and pulmonary embolisms, that could be linked to the use of NuvaRing. To discuss a potential NuvaRing lawsuit claim with one of the compassionate NuvaRing lawyers at Alonso Krangle LLP, please contact 1-800-403-6191 or visit the website, FightForVictims.com. Alonso Krangle LLP is headquartered in Long Island, New York, with offices in New York City, and New Jersey.

For more information about Alonso Krangle or to join the fight and be a part of our team, please contact us at 1-800-403-6191 or visit our website, FightForVictims.com.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10963121.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Law Firm Aggressively Litigating against Birth Control Makers for their Newer, but Allegedly Unsafer Products: Nuvaring, Yaz, BeYaz, Yasmin, Ocella, Gianvi
2. DrugRisk Center Announces Court Postponement of NuvaRing Lawsuits
3. DrugRisk Update: NuvaRing Lawsuit Trials to Begin This Year
4. NuvaRing Blood-Clotting Victims Still Eligible to File Lawsuits Through Resource4thePeople
5. NuvaRing Lawsuit Filed on Behalf of a South Carolina Woman who Developed Two Blood Clots While Using NuvaRing, Reports Wright & Schulte LLC
6. Federal NuvaRing Blood-Clotting Lawsuits Report: Resource4thePeople Updates Consumers with News That First Bellwether Trial Rescheduled to July
7. NuvaRing Blood-Clotting Claims Now Being Investigated by Resource4thePeople Attorneys
8. DrugRisks Center NuvaRing Lawsuit News: Drug Maker May Have Concealed Risks
9. 2013 NuvaRing Blood-Clotting Allegations Inquiries Eligible for Review by Resource4thePeople Attorneys
10. Rescheduling of First NuvaRing Lawsuit Trials in State, Federal NuvaRing Lawsuit Litigation, Reports Wright & Schulte LLC
11. First NuvaRing Lawsuits in State, Federal NuvaRing Litigations Set to Head to Trial Later This Year, Alonso Krangle LLP Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: